Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Apr 19, 2022 3:19pm
187 Views
Post# 34614184

RE:U.S. funding 1.6B$ for Novavax's COVID-19

RE:U.S. funding 1.6B$ for Novavax's COVID-19
ScienceFirst wrote: Examples of canadian-made Novavax vaccine that shines worldwide and that could happen to TLT, if it answers a specific unmet need:


U.S. funding to now cover study of Novavax's COVID-19 shot in adolescents

Feb 7, 2022 (Reuters) - Novavax Inc (NVAX.O) said on Monday U.S. government funding for its COVID-19 vaccine had been expanded to cover a late-stage study in adolescents with a booster component.

Novavax in July 2020 had received $1.6 billion in funding to develop its protein-based vaccine under a government program aimed at accelerating access to coronavirus vaccines and treatments, formerly called Operation Warp Speed.


Swissmedic grants conditional marketing authorization for Novavax COVID-19 vaccine for individuals aged 18 years or older in Switzerland.

Feb. 13, 2022 - 
Singapore grants interim approval for Novavax's COVID-19 ...

A
pril 14, 2022 - Thai FDA grants EUA to Novavax-Serum Institute's Covid-19 ...


 

At this point, I'm all for TLT continuing to pursue a comparable/better vaccine, but only as long as it continues to be fully government funded.  I'd rather see any limited company funds/private funding be targeted for ACT development & possibly advancing anti-viral treatment studies.

Protein-based vaccines may be the next big game-changers for Covid-19 prevention imo.  They are showing similar efficacy to that of mRNA-based vaccines & a big advantage over mRNA is that they can be stored in a standard vaccine fridge, which allows for easier storage, transport & delivery.  Such an advantage will help lower-income countries that are ill-equipped for cold storage handling.

 

<< Previous
Bullboard Posts
Next >>